Last reviewed · How we verify

Berkeley Eye Center — Portfolio Competitive Intelligence Brief

Berkeley Eye Center pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mix-and-Match PanOptix/Vivity Mix-and-Match PanOptix/Vivity marketed Ophthalmology
Clareon PanOptix PRO Clareon PanOptix PRO marketed Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Berkeley Eye Center:

Cite this brief

Drug Landscape (2026). Berkeley Eye Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/berkeley-eye-center. Accessed 2026-06-10.

Related